ArticleContact dermatitis2026
Cosmetic Adverse Reactions and Prognostic Factors: A Retrospective Cohort Study in Wuhan, China.
Article in Contact dermatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDespite the increasing prevalence of cosmetic-related adverse reactions, their potential prognoses and associated risk factors have received limited attention within the medical community.
methodsA retrospective analysis was conducted on 7794 cases of cosmetics-related adverse reactions reported in Wuhan, China, from 2017 to 2023. Data were collected from multiple sources, including medical institutions, cosmetic manufacturers, distributors, individual consumers and regulatory agencies. Demographic characteristics, clinical diagnoses, symptom profiles and allergy histories were systematically analysed using descriptive statistics. Cases were stratified by recovery outcome into complete versus incomplete groups to identify prognostic factors. Comparative analyses were performed using χ2 tests, with statistically significant variables (p < 0.05) further evaluated through multivariate logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs). All statistical analyses were performed using SPSS version 25.0, with a significance level set at p < 0.05.
resultsAmong the 7794 patients, the majority (76.56%) achieved complete recovery, while a substantial proportion (23.44%) experienced persistent or permanent symptoms, such as post-inflammatory hyperpigmentation (PIH), atrophic scarring and other forms of skin damage. Statistical analysis identified age and a history of allergies as significant risk factors for long-term skin damage. Patients under 20 years of age were 2.06 times more likely to suffer persistent or permanent symptoms compared to those over 50 years (p = 0.000). Additionally, individuals with a history of food allergy were 3.16 times more prone to long-term skin damage (p < 0.05). A history of drug allergy also significantly increased the risk, with an OR of 1.887 (95% CI: 1.34, 2.66; p = 0.000).
conclusionThis study identified younger age (< 20 years) and a history of food or drug allergies as significant risk factors for long-term symptoms following cosmetic adverse reactions. These insights assist dermatologists in recognising high-risk individuals and guiding tailored preventive strategies. Integrating these indicators into clinical evaluation and patient counselling may enhance early intervention, ultimately reducing the likelihood of persistent or irreversible cutaneous sequelae. Overall, the findings highlight the importance of individualised risk assessment and proactive management in ensuring cosmetic safety and optimising dermatological and public health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.